These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 33972682)

  • 1. Functional inhibition of cancer stemness-related protein DPP4 rescues tyrosine kinase inhibitor resistance in renal cell carcinoma.
    Kamada S; Namekawa T; Ikeda K; Suzuki T; Kagawa M; Takeshita H; Yano A; Okamoto K; Ichikawa T; Horie-Inoue K; Kawakami S; Inoue S
    Oncogene; 2021 Jun; 40(22):3899-3913. PubMed ID: 33972682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice.
    Nishina S; Yamauchi A; Kawaguchi T; Kaku K; Goto M; Sasaki K; Hara Y; Tomiyama Y; Kuribayashi F; Torimura T; Hino K
    Cell Mol Gastroenterol Hepatol; 2019; 7(1):115-134. PubMed ID: 30510994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative neoadjuvant targeted therapy remodels intra-tumoral heterogeneity of clear-cell renal cell carcinoma and ferroptosis inhibition induces resistance progression.
    Chen WJ; Pan XW; Song X; Liu ZC; Xu D; Chen JX; Dong KQ; Di SC; Ye JQ; Gan SS; Wang LH; Zhou W; Cui XG
    Cancer Lett; 2024 Jul; 593():216963. PubMed ID: 38768682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptidyl Peptidase IV as a Prognostic Marker and Therapeutic Target in Papillary Thyroid Carcinoma.
    Lee JJ; Wang TY; Liu CL; Chien MN; Chen MJ; Hsu YC; Leung CH; Cheng SP
    J Clin Endocrinol Metab; 2017 Aug; 102(8):2930-2940. PubMed ID: 28575350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway.
    Gao Y; Li J; Qiao N; Meng Q; Zhang M; Wang X; Jia J; Yang S; Qu C; Li W; Wang D
    Oncotarget; 2016 Sep; 7(39):63374-63387. PubMed ID: 27556517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.
    Bridgeman VL; Wan E; Foo S; Nathan MR; Welti JC; Frentzas S; Vermeulen PB; Preece N; Springer CJ; Powles T; Nathan PD; Larkin J; Gore M; Vasudev NS; Reynolds AR
    Mol Cancer Ther; 2016 Jan; 15(1):172-83. PubMed ID: 26487278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Targeting of Sunitinib-Induced AR Phosphorylation in Renal Cell Carcinoma.
    Adelaiye-Ogala R; Damayanti NP; Orillion AR; Arisa S; Chintala S; Titus MA; Kao C; Pili R
    Cancer Res; 2018 Jun; 78(11):2886-2896. PubMed ID: 29572225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
    D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
    J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
    Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
    Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential repurposing of DPP4 inhibitors for target therapy resistance in renal cell carcinoma.
    Horie K; Inoue S
    Oncotarget; 2023 Sep; 14():807-808. PubMed ID: 37713333
    [No Abstract]   [Full Text] [Related]  

  • 11. Sunitinib induces early histomolecular changes in a subset of renal cancer cells that contribute to resistance.
    Lichner Z; Saleeb R; Butz H; Ding Q; Nofech-Mozes R; Riad S; Farag M; Varkouhi AK; Dos Santos CC; Kapus A; Yousef GM
    FASEB J; 2019 Jan; 33(1):1347-1359. PubMed ID: 30148679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.
    Su SC; Hu X; Kenney PA; Merrill MM; Babaian KN; Zhang XY; Maity T; Yang SF; Lin X; Wood CG
    Clin Cancer Res; 2013 Dec; 19(23):6461-72. PubMed ID: 24122794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.
    Hammers HJ; Verheul HM; Salumbides B; Sharma R; Rudek M; Jaspers J; Shah P; Ellis L; Shen L; Paesante S; Dykema K; Furge K; Teh BT; Netto G; Pili R
    Mol Cancer Ther; 2010 Jun; 9(6):1525-35. PubMed ID: 20501804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sunitinib treatment promotes metastasis of drug-resistant renal cell carcinoma via TFE3 signaling pathway.
    Li L; Zhao S; Liu Z; Zhang N; Pang S; Liu J; Liu C; Fan Y
    Cell Death Dis; 2021 Feb; 12(2):220. PubMed ID: 33637706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Splice variants of lysosome‑associated membrane proteins 2A and 2B are involved in sunitinib resistance in human renal cell carcinoma cells.
    Nishikawa R; Osaki M; Sasaki R; Ishikawa M; Yumioka T; Yamaguchi N; Iwamoto H; Honda M; Kabuta T; Takenaka A; Okada F
    Oncol Rep; 2020 Nov; 44(5):1810-1820. PubMed ID: 32901843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolomics Reveals Tyrosine Kinase Inhibitor Resistance-Associated Metabolic Events in Human Metastatic Renal Cancer Cells.
    Amaro F; Carvalho M; Bastos ML; Guedes de Pinho P; Pinto J
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model.
    Diaz-Montero CM; Mao FJ; Barnard J; Parker Y; Zamanian-Daryoush M; Pink JJ; Finke JH; Rini BI; Lindner DJ
    Br J Cancer; 2016 Oct; 115(8):920-928. PubMed ID: 27560553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury.
    Reichetzeder C; von Websky K; Tsuprykov O; Mohagheghi Samarin A; Falke LG; Dwi Putra SE; Hasan AA; Antonenko V; Curato C; Rippmann J; Klein T; Hocher B
    Br J Pharmacol; 2017 Jul; 174(14):2273-2286. PubMed ID: 28423178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DPP4 inhibition by sitagliptin attenuates LPS-induced lung injury in mice.
    Kawasaki T; Chen W; Htwe YM; Tatsumi K; Dudek SM
    Am J Physiol Lung Cell Mol Physiol; 2018 Nov; 315(5):L834-L845. PubMed ID: 30188745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EIF3D promotes sunitinib resistance of renal cell carcinoma by interacting with GRP78 and inhibiting its degradation.
    Huang H; Gao Y; Liu A; Yang X; Huang F; Xu L; Danfeng X; Chen L
    EBioMedicine; 2019 Nov; 49():189-201. PubMed ID: 31669222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.